- Patient has measurable disease on CT scan or MRI to be performed within 4 weeks before randomization (measurability criteria according to RECIST 1.1, non-nodal lesions ≥10 mm, lymph nodes ≥15mm) OR evaluable disease i.e. patient with non-measurable metastases but elevated serum tumor-marker (CEA at least >2xULN).